DOCSLIB.ORG

Vasopeptidase Inhibition with Omapatrilat in Chronic Heart Failure: Acute and Long-Term Hemodynamic and Neurohumoral Effects Dougal R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vasopeptidase Inhibition with Omapatrilat in Chronic Heart Failure: Acute and Long-Term Hemodynamic and Neurohumoral Effects Dougal R View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 39, No. 12, 2002 © 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01881-8 Vasopeptidase Inhibition With Omapatrilat in Chronic Heart Failure: Acute and Long-Term Hemodynamic and Neurohumoral Effects Dougal R. McClean, MD,* Hamid Ikram, MD, PHD,* Sukh Mehta, MD,† J. Thomas Heywood, MD,‡ Michel F. Rousseau, MD,§ Alan L. Niederman, MD,࿣ Rafael F. Sequeira, MD,¶ Eckart Fleck, MD,# Steven N. Singh, MD,** Benoit Coutu, MD,†† Peter Hanrath, MD,‡‡ Michel Komajda, MD,§§ Catherine C. Bryson,࿣࿣ Chunlin Qian, PHD,࿣࿣ James J. Hanyok, PHARMD,࿣࿣ for the Omapatrilat Hemodynamic Study Group Christchurch, New Zealand; San Bernadino and Loma Linda, California; Brussels, Belgium; Fort Lauderdale and Miami, Florida; Berlin and Aachen, Germany; Washington, DC; Montreal, Canada; Paris, France; and Princeton, New Jersey OBJECTIVES We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure. BACKGROUND Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopep- tidase and ACE with omapatrilat may represent a new treatment strategy in CHF. METHODS Three hundred and sixty-nine patients with symptomatic heart failure were randomized to double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179 patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks. RESULTS Acutely, the 10 mg, 20 mg and 40 mg doses of omapatrilat produced greater reductions in pulmonary capillary wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular resistance compared with 2.5 mg. Higher doses were associated with greater increases in vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat 20 mg and 40 mg showed greater falls from baseline in PCWP (40 mg:0hto12haverage change Ϫ7.3 Ϯ 0.8 mm Hg) and SBP (40 mg: Ϫ11.7 Ϯ 1.7 mm Hg) than 2.5 mg (both p Ͻ 0.01 vs. 2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups. CONCLUSIONS In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a promising new agent in CHF. (J Am Coll Cardiol 2002;39:2034–41) © 2002 by the American College of Cardiology Foundation Angiotensin-converting enzyme (ACE) inhibition consti- in CHF (4,5). However, their therapeutic usefulness is tutes a major advance in the treatment of chronic heart limited by a short half-life, due to rapid degradation by failure (CHF), with symptomatic improvement and some neutral endopeptidase (NEP) (6). Other NEP substrates survival gains (1). However, despite the first line use of include bradykinin (7) and adrenomedullin (ADM) (8). ACE inhibitors and, more recently, beta-adrenergic block- Omapatrilat is the first of a new class of drugs known as ing agents, the prognosis of CHF remains poor (1,2). vasopeptidase inhibitors, which simultaneously inhibit both The natriuretic peptides are counter-regulatory to the NEP and ACE, resulting in increased levels of natriuretic renin-angiotensin system, causing vasodilation, diuresis and peptides and bradykinin, with a reduction in angiotensin II natriuresis (3–5). Augmentation of their levels with exog- (9,10). In patients with heart failure, omapatrilat therapy for enously administered atrial natriuretic peptide (ANP) and 24 weeks showed a similar increase in week 12 exercise brain natriuretic peptide (BNP) has resulted in a reduction tolerance but conferred more benefit than lisinopril in the in filling pressures, natriuresis and diuresis in acute studies composite of death, hospital admission or discontinuation of study treatment for worsening heart failure (11). From the *Christchurch Hospital, Christchurch, New Zealand; †San Bernadino, The purpose of this multicenter study was to evaluate the California; ‡Jerry L. Pettis Veterans Administration Medical Center, Loma Linda, hemodynamic and neurohumoral effects, safety and tolera- California; §Cliniques Universitaires Saint-Luc, Brussels, Belgium; ࿣Greater Fort bility of increasing doses of omapatrilat after a single oral Lauderdale Heart Group Research, Fort Lauderdale, Florida; ¶University of Miami/ Jackson Memorial Medical Center, Miami, Florida; #Deutsches Herzzentrum Berlin, dose and after 12 weeks of once-daily oral therapy in Berlin, Germany; **Veterans Administration Medical Center, Washington, DC; patients with symptomatic heart failure. ††Pavillon Hopital Notre-Dame, Montreal, Canada; ‡‡Medizinische Fakultat der RWTH, Aachen, Germany; §§Hoˆpital Pitieˆ-Salpetri⌸re, Paris, France; and ࿣࿣Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey. Supported by a project grant from Bristol-Myers Squibb Pharmaceutical Research METHODS Institute, Princeton, New Jersey. Manuscript received May 17, 2001; revised manuscript received March 4, 2002, Study design. Patients with stable symptomatic heart fail- accepted March 15, 2002. ure (New York Heart Association functional class II to IV), JACC Vol. 39, No. 12, 2002 McClean et al. 2035 June 19, 2002:2034–41 Hemodynamic Effects of Omapatrilat in Heart Failure Subjects were continued for 12 weeks on double-blind Abbreviations and Acronyms study drug. All other medications (except ACE inhibitors or ACE ϭ angiotensin-converting enzyme angiotensin II receptor antagonists) were restarted and ADM ϭ adrenomedullin continued throughout the 12 weeks. Outpatient evaluations ϭ ANP atrial natriuretic peptide were performed at weeks 1, 2, 4, 6 and 8. Up to four BNP ϭ brain natriuretic peptide cGMP ϭ cyclic 3Ј,5Ј-guanosine monophosphate supplemental doses of diuretics were permitted for worsen- CHF ϭ chronic heart failure ing heart failure, with no supplemental doses permitted CI ϭ cardiac index within 72 h before hemodynamic measurements. Patients ET-1 ϭ endothelin-1 were withdrawn from the study if an increase in the daily ϭ NEP neutral endopeptidase maintenance dose of diuretic or other heart failure medica- PCWP ϭ pulmonary capillary wedge pressure ϭ tion was required. The diuretic dose could be decreased to SBP systolic blood pressure Ͼ ␮ SVR ϭ systemic vascular resistance correct serum creatinine 3.0 mg/dl (265 mol/l) or to correct symptomatic hypotension. After 12 weeks, patients underwent a second right heart left ventricular ejection fraction Յ40% and in sinus rhythm catheterization. On the morning of the next day, the study were eligible for enrollment in this multicenter double- medication was administered after two consecutive predose blind, randomized study. The protocol was approved by recordings showed Յ10% variability in PCWP and CI; local ethical committees, and all patients gave written, repeat measurements were performed over a similar 24-h informed consent. period as on day 1. All other medications were withheld Studies in normal human volunteers have shown evidence during the 24-h period. of significant ACE inhibition with 2.5 mg to 75 mg doses Methodology. Hemodynamic assessment was performed of omapatrilat (12,13), while dose-related NEP inhibition, the day after placement of a balloon-tipped thermodilution as measured by changes in urinary ANP and urinary cyclic catheter in the pulmonary artery. Pulmonary arterial pres- 3Ј,5Ј-guanosine monophosphate (cGMP), was shown from sures and electrocardiogram were measured continuously, the 7.5-mg to the 75-mg dose (12). In contrast, the 2.5-mg cardiac output was measured by the thermodilution tech- omapatrilat dose, although showing selective ACE inhibi- nique, and arterial blood pressures by brachial sphygmoma- tion, did not change urinary ANP and cGMP. Since ethical nometry. All measurements were performed in triplicate in considerations excluded a placebo control, the 2.5-mg dose the semisupine position. Cardiac index and systemic vascu- was used as an active control. lar resistance (SVR) were calculated using standard formulas The study was conducted in two sequential, separate (14). Physician and subject assessments of the change in panels. In panel I, patients were randomized to omapatrilat functional status were performed at three months or on 2.5 mg, 5 mg or 10 mg once daily. In panel II, patients were withdrawal from study using a global assessment scale: randomized to omapatrilat 2.5 mg, 20 mg or 40 mg once improved (greatly, moderately or slightly), unchanged or daily. An analysis of safety data from the completed panel I worsened. Subjects participating in the neurohormonal was performed before panel II started. Patients who were in substudy had venous blood drawn during both hemody- panel I were not eligible for panel II. namic monitoring periods (day 1 and week 12), predose and After enrollment, there was a 2- to 14-day single-blind at 3 h, 12 h and 24 h after dose. placebo lead-in period, where patients were stabilized on Measurement of plasma ANP, BNP, cGMP, ADM, diuretics and concomitant cardiac medications, with doses aldosterone, endothelin-1 (ET-1), renin and ACE activity remaining stable for Ն2 days before right heart catheteriza- was performed by radioimmunoassay,
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Next Generation Multifunctional Angiotensin Receptor Blockers
    Hypertension Research (2009) 32, 826–834 & 2009 The Japanese Society of Hypertension All rights reserved 0916-9636/09 $32.00 www.nature.com/hr REVIEW Next generation multifunctional angiotensin receptor blockers Theodore W Kurtz1 and Uwe Klein2 Angiotensin receptor blockers (ARBs) are well-tolerated drugs that are known to be useful for inhibiting activity of the renin– angiotensin (RAS) system, treating hypertension and reducing the risk for cardiovascular disease. However, inhibition of the RAS does not control all pathophysiological mechanisms of hypertension or cardiovascular risk and many patients continue to suffer from cardiovascular events and metabolic disturbances despite being treated with an ARB, an angiotensin-converting enzyme inhibitor or both, in addition to other standard therapies for cardiovascular disease. Recently, it has become apparent that bifunctional molecules can be designed that do more than just block AT1 receptors and that can target additional mechanisms of hypertension, cardiovascular disease and diabetes besides just increased activity of the renin–angiotensin system. Specifically, next generation ARBs are becoming available that are intended to not only antagonize AT1 receptors, but also block endothelin receptors, function as nitric oxide donors, inhibit neprilysin activity and increase natriuretic peptide levels, or stimulate the peroxisome proliferator-activated receptor c (PPARc). In this review, we: (1) discuss the potential importance of multifunctional ARBs that can reduce cardiovascular and metabolic
    [Show full text]
  • Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: a Meta-Analysis
    European Journal of Heart Failure (2016) doi:10.1002/ejhf.603 Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis Scott D. Solomon1*, Brian Claggett1, John J.V. McMurray2, Adrian F. Hernandez3, and Gregg C. Fonarow4 1Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2University of Glasgow, Glasgow, UK; 3Duke University, Durham, NC, USA; and 4Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA Received 1 March 2016; revised 25 May 2016; accepted 3 June 2016 Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. While sacubitril/valsartan is the only currently available drug in its class, there are two prior clinical trials in heart failure with omapatrilat, another combined neprilysin/RAS inhibitor. Using all available evidence can inform clinicians and policy-makers. ..................................................................................................................................................................... Methods We performed a meta-analysis using data from three trials in heart failure with reduced EF that compared combined and results neprilysin/RAS inhibition with RAS inhibition alone and reported clinical outcomes: IMPRESS (n = 573), OVERTURE (n = 5770), and PARADIGM-HF (n = 8399). We assessed the pooled hazard ratio (HR) for all-cause death or heart failure hospitalization, and for all-cause mortality in random-effects models, comparing combined neprilysin/RAS inhibition with ACE inhibition alone. The composite outcome of death or heart failure hospitalization was reduced numerically in patients receiving combined neprilysin/RAS inhibition in all three trials, with a pooled HR of 0.86, 95% confidence interval (CI) 0.76–0.97, P = 0.013.
    [Show full text]
  • Narrative Review in the Current Role of Angiotensin Receptor- Neprilysin Inhibitors
    518 Review Article on Heart Failure Update and Advances in 2021 Page 1 of 9 Narrative review in the current role of angiotensin receptor- neprilysin inhibitors Jose B. Cruz Rodriguez1, Cameron Cu2, Tariq Siddiqui1 1Division of Cardiovascular Diseases, 2Department of Internal Medicine, Texas Tech University Health Science Center El Paso, El Paso, TX, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: JB Cruz Rodriguez, T Siddiqui; (III) Provision of study materials or patients: JB Cruz Rodriguez, C Cu; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Jose B. Cruz Rodriguez. Division of Cardiovascular Diseases, Texas Tech University Health Science Center El Paso. 4800 Alberta Avenue, El Paso, TX 79905, USA. Email: [email protected]. Abstract: Heart failure (HF) accounts for a tremendous burden on health care systems and the society. Since the landmark PARADIGM-HF trial, sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitor (ARNI) showed superiority to enalapril in patients with HF with reduced ejection fraction (HFrEF). We performed a narrative literature review, hand-searched the reference lists of included articles and relevant reviews. Inhibition of neprilysin increases bradykinin, natriuretic peptides and adrenomedullin levels counteract the neurohormal activation that leads to sodium retention, vasoconstriction, and cardiac remodeling. In PARADIGM-HF the primary outcome of CV death or HF hospitalization was reduced 20% in the ARNI group (HR 0.80, P<0.001) similar to mortality due to cardiovascular cause (HR 0.80, P<0.001) in patients with HFrEF, rendering a number needed to treat of 21 patients.
    [Show full text]
  • Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact
    Journal of Cardiac Failure Vol. 21 No. 9 2015 Review Article Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact JONATHAN BUGGEY, MD,1 ROBERT J. MENTZ, MD,1,2 ADAM D. DEVORE, MD,1,2 AND ERIC J. VELAZQUEZ, MD1,2 Durham, North Carolina ABSTRACT Heart failure (HF) is an increasingly common syndrome associated with high mortality and economic burden, and there has been a paucity over the past decade of new pharmacotherapies that improve outcomes. However, recent data from a large randomized controlled trial compared the novel agent LCZ696, a dual-acting angiotensin receptor blocker and neprilysin inhibitor (ARNi), with the well estab- lished angiotensin-converting enzyme (ACE) inhibitor enalapril and found significant reduction in mortal- ity among the chronic reduced ejection fraction HF population. Preclinical and clinical data suggest that neprilysin inhibition provides beneficial outcomes in HF patients by preventing the degradation of natriuretic peptides and thereby promoting natriuresis and vasodilatation and counteracting the negative cardiorenal effects of the up-regulated renin-angiotensin-aldosterone system. Agents such as omapatrilat combined neprilysin and ACE inhibition but had increased rates of angioedema. Goals of an improved safety profile provided the rationale for the development of the ARNi LCZ696. Along with significant reductions in mortality and hospitalizations, clinical trials suggest that LCZ696 may improve surrogate markers of HF severity. In this paper, we review the preclinical and clinical data that led to the develop- ment of LCZ696, the understanding of the underlying mechanistic action, and the robust clinical impact that LCZ696 may have in the near future.
    [Show full text]
  • 207620Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207620Orig1s000 SUMMARY REVIEW Cross Discipline Team Leader Review 4. Nonclinical Pharmacology/Toxicology According to Dr. Link’s review, the preclinical toxicology program was well-conducted and thorough and the application can be approved from a pharmacology/toxicology perspective. Toxicology:3 Target organs for LCZ696 and/or sacubitril toxicity included the kidney, red blood cells, heart and gastrointestinal tract. In brief, findings included: renal juxtaglomerular hypertrophy/hyperplasia in the rat and monkey and renal tubular changes (tubular basophilia, cytoplasmic vacuolation and single cell necrosis) in the monkey; reversible changes in hematology parameters (e.g., decreases in red blood cell count, hemoglobin concentration, hematocrit, and reticulocytes); decreased heart weights without histopathological findings; and reversible microscopic changes of focal glandular stomach mucosal erosion and mixed cell inflammation in rats and emesis and diarrhea without histologic correlates in the cynomolgus monkey. According to Dr. Link, these findings reflected adaptive responses or resulted from exaggerated pharmacodynamic responses to high doses and do not raise concern for safe use in humans. See pages 240 to 242 of Dr. Link’s review for further discussion of these findings. Genotoxicity and carcinogenicity: According to the Carcinogenicity study review, sacubitril had no effect on survival or tumor incidence in mice or rats. In genetic toxicity studies of LCZ696, sacubitril, and the active metabolite LBQ657, there was no evidence of genotoxic potential. Reproductive toxicology: LCZ696 had no effect on fertility in rats. In embryo-fetal development studies in rats and rabbits, treatment with LCZ696 during organogenesis resulted in increased embryo-fetal lethality at clinically relevant doses.
    [Show full text]
  • Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
    Int J Heart Fail. 2020 Apr;2(2):73-90 https://doi.org/10.36628/ijhf.2020.0002 pISSN 2636-154X·eISSN 2636-1558 Review Article Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure Barry Greenberg , MD Sulpizio Family Cardiovascular Center and University of California, San Diego Medical Center, La Jolla, CA, USA Received: Jan 1, 2020 ABSTRACT Revised: Mar 1, 2020 Accepted: Mar 4, 2020 Recognition that neurohormonal activation plays a central role in the pathogenesis of heart Correspondence to failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs), Barry Greenberg, MD angiotensin receptor blockers, mineralocorticoid receptor antagonists and beta blockers. Sulpizio Family Cardiovascular Center and University of California, San Diego Medical While there has been substantial success with these neurohormonal blocking drugs in Center, 9454 Medical Center Drive, La Jolla, patients with HF with reduced ejection fraction (HFrEF), persistently high rates of morbidity CA 92037-7411, USA. and mortality in this population underscore the need for more effective therapies. As part E-mail: [email protected] of the systemic neurohormonal activation that takes place in patients with HF, systems that counteract the adverse effect of the renin angiotensin aldosterone system (RAAS) and Copyright © 2020. Korean Society of Heart Failure sympathetic nervous system (SNS) are also activated. Evidence that neprilysin metabolizes This is an Open Access article distributed many of the effector molecules produced by these counter-regulatory systems raised the under the terms of the Creative Commons possibility that inhibition of this enzyme might be beneficial. However, since angiotensin Attribution Non-Commercial License (https:// II is a substrate of neprilysin, inhibition of the enzyme alone would increase levels of this creativecommons.org/licenses/by-nc/4.0) peptide.
    [Show full text]
  • Telmisartan Versus Angiotension-Converting
    Journal of Human Hypertension (2009) 23, 339–349 & 2009 Macmillan Publishers Limited All rights reserved 0950-9240/09 $32.00 www.nature.com/jhh ORIGINAL ARTICLE Telmisartan versus angiotension- converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials Z Zou1,3, G-L Xi2,3, H-B Yuan1, Q-F Zhu1 and X-Y Shi1 1Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China and 2Center for New Drug Evaluation, Institute of Basic Medical Science, Second Military Medical University, Shanghai, People’s Republic of China Telmisartan and angiotensin-converting enzyme inhibi- 0.33–2.62). Telmisartan also showed a greater DBP tors (ACEIs) are both effective and widely used response rate than enalapril (relative risk (RR) 1.15, antihypertensive drugs targeting renin–angiotensin– 95% CI 1.05–1.26), ramipril (RR 1.34, 95% CI 1.11–1.61) aldosterone system. The study aimed to estimate the and perindopril (RR 1.22, 95% CI 1.05–1.41). There was efficacy and tolerability of telmisartan in comparison no statistical difference in DBP reduction or therapeutic with different ACEIs as monotherapy in the treatment of response rate between telmisartan and lisinopril (WMD hypertension. Cochrane Central Register of Controlled À0.30, 95% CI À0.65 to 0.05; RR 0.99, 95% CI 0.80–1.23, Trials, PubMed and Embase were searched for relevant respectively). Telmisartan had fewer drug-related studies. A meta-analysis of all randomized controlled adverse events than enalapril (RR 0.57, 95% CI 0.44–0.74), trials fulfilling the predefined criteria was performed.
    [Show full text]
  • Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension
    J Am Soc Nephrol 12: 2280–2287, 2001 Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension THOMAS QUASCHNING,* LIVIUS V. D’USCIO,* SIDNEY SHAW,† HERMANN-JOSEF GRO¨ NE,‡ FRANK RUSCHITZKA,§ and THOMAS F. LU¨ SCHER§ *Cardiovascular Research, Institute of Physiology, University of Zu¨rich, Zu¨rich, Switzerland; †Clinical Research, Inselspital, University of Bern, Bern, Switzerland; ‡Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; and §Cardiovascular Center and Cardiology, University of Zu¨rich, Zu¨rich, Switzerland. Abstract. Renovascular hemodynamics plays a pivotal role in 6%; P Ͻ 0.05) as well as contractions to endothelin-1 (ET-1) the regulation of BP. The effect of the vasopeptidase inhibitor (98 Ϯ 5% versus 128 Ϯ 5%; P Ͻ 0.05) and big ET-1 (47 Ϯ 6% omapatrilat (O) and the ACE-inhibitor captopril (C) on endo- versus 116 Ϯ 7%; P Ͻ 0.05) were markedly reduced as thelial function in the renal circulation in salt-induced hyper- compared with control animals, whereas standardized aortic tension were investigated. Dahl salt-sensitive rats (n ϭ 6 per weight and heart weight (4.9 Ϯ 0.4 versus 3.2 Ϯ 0.3 g/kg; group) on standard or salt-enriched chow were treated for 8 wk P Ͻ 0.05) increased. Treatment with O restored endotheli- with O (36 Ϯ 4 mg/kg per d), C (94 Ϯ 2 mg/kg per d), or um-dependent relaxations (88 Ϯ 6%; P Ͻ 0.05 versus C) placebo. Renal arteries were suspended in organ chambers for and contractions to ET-1 (120 Ϯ 6%) and big ET-1 (98 Ϯ isometric tension recording.
    [Show full text]
  • Reacciones Adversas Causadas Por Fármacos Activos En El Sistema Renina Angiotensina Aldosterona: Descripción De Un Nuevo Síndrome
    Programa de Doctorado en Medicina Clínica REACCIONES ADVERSAS CAUSADAS POR FÁRMACOS ACTIVOS EN EL SISTEMA RENINA ANGIOTENSINA ALDOSTERONA: DESCRIPCIÓN DE UN NUEVO SÍNDROME Tesis Doctoral presentada por ANA MARGARITA MONTORO DE FRANCISCO Directores: DR. MELCHOR ÁLVAREZ DE MON SOTO DRA. AMELIA GARCÍA LUQUE Alcalá de Henares, 2016 A mi familia. Agradecimientos Esta tesis doctoral se ha realizado en el Servicio de Alergología del Hospital Central de la Defensa “Gómez Ulla;” quiero agradecer a la Dirección del Hospital y a los Jefes de los Servicios la posibilidad que me han dado para poder llevar a cabo este trabajo desde el año 2009. A la Doctora Amelia García Luque del Servicio de Farmacología Clínica por su orientación, apoyo, ánimo y ayuda desde los momentos preliminares hasta las correcciones del manuscrito. Destacar su afán de superación contagioso y sobre todo su accesibilidad y calor humano. A todos los miembros del Servicio de Alergología, especialmente al Doctor José María Mateos Galván, con quién coincidí en los dos primeros años mi formación como especialista en Alergología por su espíritu crítico y capacidad de análisis. A los médicos internos residentes que he tutorizado desde 2009 por su buena actitud y colaboración. A la Doctora María Rubio Sotés, Jefa de Servicio de Alergología del Hospital General Universitario Gregorio Marañón por su impagable ejemplo y sus consejos durante mis años de formación. A las enfermeras del Servicio de Alergología: Esperanza, Paloma, Teresa y Beatriz por su colaboración desinteresada. A todos los pacientes que han participado en este trabajo por su buena disposición y constancia en su colaboración. A mis padres, porque sin ellos no habría logrado ninguna de las metas que me propuse y no sería lo que soy hoy.
    [Show full text]
  • Vasopeptidase Inhibition: a New Treatment Approach for Endothelial Dysfunction
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 63, Supplement 84 (2003), pp. S54–S57 Vasopeptidase inhibition: A new treatment approach for endothelial dysfunction THOMAS QUASCHNING,JAN GALLE, and CHRISTOPH WANNER Department of Medicine, Division of Nephrology, University Clinic Wu¨rzburg, Wu¨rzburg, Germany Vasopeptidase inhibition: A new treatment approach for endo- of potent paracrine mediators such as nitric oxide (NO), thelial dysfunction. Angiotensin-converting enzyme (ACE) in- angiotensin II, and endothelin-1 (Fig. 1). The different hibition is a well-established principle in the treatment of endo- circulating and local systems show important synergisms thelial dysfunction. Numerous preclinical and clinical studies have clearly demonstrated the beneficial effects of inhibiting and interactions. They may either have synergistic effects the renin-angiotensin-aldosterone system (RAS) in states of im- or may be the functional counterpart of another system paired endothelial function. The successful use of ACE inhibi- in a subtle multivariate balance. As such, atrial natriuretic tors encouraged attempts to inhibit other key enzymes in the peptides (ANP) counteract the effects of angiotensin II. regulation of vascular tone, such as the neutral endopeptidase (NEP). Similar to ACE, NEP is an endothelial cell surface metal- Since effects of endothelium-derived substances are not loproteinase that is involved in the degradation of several regu- limited to vasoconstriction or vasodilatation, but may also latory peptides, including the natriuretic peptides, and, thus, include regulation of mitogenesis, endothelial dysfunc- NEP inhibition augments vasodilatation and natriuresis through tion not only affects the function of the cardiovascular increased levels of atrial natriuretic peptide (ANP).
    [Show full text]
  • Neprilysin Inhibition with Sacubitril/Valsartan in the Treatment of Heart Failure
    Journal of Clinical Pharmacy and Therapeutics, 2016, 41,119–127 doi: 10.1111/jcpt.12363 Review Article Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck A. J. Ansara*† PharmD BCPS-AQ Cardiology, D. M. Kolanczyk‡§ PharmD BCPS-AQ Cardiology and J. M. Koehler†¶ PharmD FCCP *Department of Pharmacy, Indiana University Health Methodist Hospital, Indianapolis, IN, †Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, ‡Department of Pharmacy, Loyola University Medical Center, Maywood, IL, §Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL, and ¶Pulmonary Rehabilitation and Transitional Care, Indiana University Health, Indianapolis, IN, USA Received 14 August 2015, Accepted 21 January 2016 Keywords: angiotensin, endopeptidase, heart failure, LCZ696, natriuretic peptides, neprilysin inhibitor, omapatrilat, sacubitril, valsartan When compared to ACE inhibitor therapy in systolic heart SUMMARY failure patients, sacubitril/valsartan demonstrated reductions in What is known and objective: Heart failure remains a leading all-cause mortality and hospitalization due to heart failure while cause of morbidity and mortality worldwide. Advanced thera- maintaining a similar safety profile. pies have prolonged survival in patients with advanced heart What is new and conclusion: A formulation that contains both failure, but pharmacotherapeutic optimization remains the sacubitril and valsartan was manufactured and approved by the mainstay of treatment. It has been over 10 years since the last FDA in July 2015 for the reduction of mortality and hospitaliza- mortality-reducing medication has been approved by the Food tion in systolic heart failure patients. The new medication offers and Drug Administration.
    [Show full text]